Navigating U.S. Policy: How Data and Transparency Guide Our Efforts

By Adam Gluck, Head, U.S. and Specialty Care Corporate Affairs

Policy is sometimes viewed in contrast to medicine or healthcare, with the field perceived as more of an “art” than a “science” in D.C. and the 50 U.S. states.

We believe, however, that the science—in this case, the insights gleaned from tracking and sharing data about our healthcare ecosystem—can serve as a signal in our noisy world, pointing us toward patient-centered solutions.

Sanofi recently published its annual Pricing Principles report, highlighting how 2025 U.S. pricing actions reinforce our commitment to transparency and data-driven decision making. This year’s report holds a trove of insights into how Sanofi prices medicines  in the U.S., which we hope can inform an open dialogue to improve patient access and affordability.

The 2026 Pricing Principles report marks 10 years of public data  on our pricing and the U.S. environment impacting patient affordability. These figures are more than numbers on a page; our data helps mark where we and our industry have been and what lies ahead, signaling emerging trends that could disrupt how patients access and pay for medicines.

This year’s report features the latest Sanofi data on pricing and industry middlemen.

• 3.4% decrease in average aggregate net price—the amount Sanofi receives for its medicines—for our portfolio of medicines and vaccines compared to 2024
• 39% of Sanofi’s gross sales paid as rebates to PBMs and health plans last year explicitly to secure affordable access to our medicines for patients who need them
• 23% increase in fees—or service charges—paid on top of negotiated rebates to PBMs and health plans within Sanofi’s specialty medicines portfolio since 2024

Despite Sanofi’s payment of increasing rebates and fees to secure a place on PBM formularies, patients still must navigate high deductibles and co-insurance that often prohibit access to a medically necessary therapy.

Guided by a decade of data shared with the public, Sanofi has pushed for meaningful reforms across the U.S. healthcare system. Our advocacy has helped spur impactful changes at the state and federal levels, from lowering out-of-pocket costs for vaccines and specialty medicines to increased scrutiny of how PBM practices can raise patients' costs, helping much-needed PBM reforms pass Congress earlier this year.

Taken together, these efforts underscore an important lesson: a patient‑first, data‑driven approach is not just the right thing to do; it’s the path that leads to results, including better access and more affordable care.

That leaves one critical question: Where is the latest data leading us next when it comes to policy?

First, we see a critical need for legislators to ensure that cost-containment strategies do not place undue financial burden on patients. We see firsthand how coverage barriers and system-level pressures are complicating timely access to medicines, particularly specialty medicines  used to treat rare, complex, or chronic conditions. These policies can lead to delayed access to care and unnecessary suffering for patients.